New York, New York - April 11, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a biotech investor spotlight for Sirona Biochem Corp . (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB).
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.
Investor video on SBM's technology!
Read the previous news release. SBM just closed a private placement of over $1 Million dollars!
http://www.sironabiochem.com/sirona-closes-non-brokered-private-placement-of-1406500/
Today's News:
Sirona Biochem Corp. (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB), announced today its abstract application to present a scientific poster at the 2012 Protein Engineering Summit (PEGS) has been accepted. Sirona Biochems scientific poster has been selected to be on display during the Difficult to Express Proteins track April 30 to May 1, 2012.
The Eighth Annual PEGS conference, to be held April 30 May 4, 2012 in Boston, MA, brings together an estimated 1,400 international decision makers in pharmaceutical, biotechnology, academia and public healthcare and focuses on the latest scientific innovations in protein engineering.
Sirona Biochems scientific poster at the PEGS conference will describe the use of its new inducer, SBM-TFC-358, and how it may be effective at improving recombinant protein yields. The poster will also include results from the latest study demonstrating the effectiveness of SBM-TFC-358 on a recalcitrant protein and comparing the compound against a widely used inducer, IPTG.
Additional studies are being conducted to further characterize SBM-TFC-358 and prepare it for commercialization.
A copy of the poster will be made available on the companys website at www.sironabiochem.com after the conference.
About Sirona Biochem Corpwww.sironabiochem.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
Wednesday, April 11, 2012
Medical Technology Stock Alert; PositiveID Corporation (OTCBB:PSID) Begins Orders of iglucose at www.iglucose.com
DELRAY BEACH, Fla. - April 11, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced it has begun taking orders of its FDA-cleared iglucose(R) mobile health system for diabetes management. Pre-orders are being accepted through the iglucose website at www.iglucose.com and the PositiveID website at www.positiveidcorp.com. PositiveID expects to commercially launch iglucose during the second quarter of 2012.
PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating blood glucose readings from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose does not require the use of a cell phone or a wireless plan.
"As we complete the final stages of preparing for the commercial launch of iglucose, we are pleased, based on consumer demand, to be able to provide the opportunity to pre-order this FDA-cleared system for diabetes management," stated William J. Caragol, Chairman and CEO of PositiveID. "Those who order will be given priority status while we initially roll-out iglucose through pilot programs with health insurers and home-healthcare providers."
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating blood glucose readings from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose does not require the use of a cell phone or a wireless plan.
"As we complete the final stages of preparing for the commercial launch of iglucose, we are pleased, based on consumer demand, to be able to provide the opportunity to pre-order this FDA-cleared system for diabetes management," stated William J. Caragol, Chairman and CEO of PositiveID. "Those who order will be given priority status while we initially roll-out iglucose through pilot programs with health insurers and home-healthcare providers."
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Biotech Investor Alert: Sirona Biochem (TSX-V: SBM) to Present Scientific Poster of Inducer Program at 2012 Protein Engineering Summit (PEGS)
Vancouver, British Columbia - April 11, 2012 (InvestorIdeas.com Newswire) Sirona Biochem Corp. ( TSX-V: SBM , OTC: SRBCF, Frankfurt: ZSB), announced today its abstract application to present a scientific poster at the 2012 Protein Engineering Summit (PEGS) has been accepted. Sirona Biochem's scientific poster has been selected to be on display during the “Difficult to Express Proteins” track April 30 to May 1, 2012.
The Eighth Annual PEGS conference, to be held April 30 - May 4, 2012 in Boston, MA, brings together an estimated 1,400 international decision makers in pharmaceutical, biotechnology, academia and public healthcare and focuses on the latest scientific innovations in protein engineering.
Sirona Biochem's scientific poster at the PEGS conference will describe the use of its new inducer, SBM-TFC-358, and how it may be effective at improving recombinant protein yields. The poster will also include results from the latest study demonstrating the effectiveness of SBM-TFC-358 on a recalcitrant protein and comparing the compound against a widely used inducer, IPTG.
Additional studies are being conducted to further characterize SBM-TFC-358 and prepare it for commercialization.
A copy of the poster will be made available on the company's website at www.sironabiochem.com after the conference.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Published at the Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
The Eighth Annual PEGS conference, to be held April 30 - May 4, 2012 in Boston, MA, brings together an estimated 1,400 international decision makers in pharmaceutical, biotechnology, academia and public healthcare and focuses on the latest scientific innovations in protein engineering.
Sirona Biochem's scientific poster at the PEGS conference will describe the use of its new inducer, SBM-TFC-358, and how it may be effective at improving recombinant protein yields. The poster will also include results from the latest study demonstrating the effectiveness of SBM-TFC-358 on a recalcitrant protein and comparing the compound against a widely used inducer, IPTG.
Additional studies are being conducted to further characterize SBM-TFC-358 and prepare it for commercialization.
A copy of the poster will be made available on the company's website at www.sironabiochem.com after the conference.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Published at the Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
Tuesday, April 10, 2012
LAST (OTCQB: LAST) Announces Incubator Portfolio of Social Networking and Biotech Companies
SANTA MONICA, CA - April 10, 2012 (Investorideas.com Newswire) - Los Angeles Syndicate of Technology, Inc. (OTCQB: LAST.OB), a Business Development Company (BDC) that incubates early stage technology companies, has announced the successful launches of the first three portfolio companies built within its technology incubator. LAST is the largest shareholder of each of the three companies including Sanguine Biosciences, a bio-specimen supplier; Virurl, Inc., a social advertising platform; and Stocktown Productions, a digital production studio.
Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner
"We are encouraged that our first three portfolio companies are generating revenue and expanding operations," said Bryce Knight, CEO of LAST. He added "We are excited to bring new team members into the LAST network to support the growth of these companies and to continue developing our second class of companies under the LAST umbrella."
About Los Angeles Syndicate of Technology - www.last.vc
Los Angeles Syndicate of Technology, Inc. (OTC: LAST.OB) is a publicly traded Business Development Company (BDC) that creates, builds, and invests in web and mobile technology companies. LAST develops digital media, consumer internet, and social networking products in its technology incubator, and has a portfolio of six companies at different stages of development. LAST's mission is to foster technology innovation in Los Angeles by partnering with the most talented entrepreneurs of southern California and providing them with the capital, support and tools to bring their ideas to market and commercialize their products.
About Sanguine Biosciences, Inc. - sanguinebio.com
Sanguine Biosciences, Inc. ("Sanguine") is an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines. Sanguine provides highly viable primary human cells and tissues to both the academic and industrial life science research communities through a new direct-to-patient platform. The current product offering spans customers' needs in the In Vitro Research & Development stage of Drug Development. Sanguine's vision is to develop into the global leader in high quality cells and tissues for life science research and development.
About Virurl, Inc. - virurl.com
Virurl, Inc. ("Virurl") is an online advertising platform that allows advertisers to incentivize people to share links with their friends. By creating a forum where users are rewarded for sharing links, the VIRURL platform empowers content creators and advertisers to tap the organic social networks of the web to drive traffic to their sites. Virurl is a "human-powered" advertising engine, enabling users to earn cash and rewards for what they are already doing everyday - sharing links with their friends.
About Stocktown Productions, Inc. - stocktownproductions.com
Stocktown Productions, Inc. ("Stocktown") is a digital production studio based in Santa Monica, California, specializing in video, animation and 3-D visual effects. In addition to video production, Stocktown provides innovative web and graphic design - bringing an original style and cutting-edge concepts to each project.
Forward-Looking Statements
Statements included in this release related to Los Angeles Syndicate of Technology, Inc. and its portfolio companies constitute or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the inherent uncertainty of investing in early-stage technology companies, the technological and financial difficulties inherent in these activities, and the Company's ability to estimate accurately net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the Company's reports filed with the Securities and Exchange Commission.
Contact Information
Contact:
Los Angeles Syndicate of Technology, Inc.
Bryce Knight
310) 694-0640
www.last.vc
Published at Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure- Investorideas.com and its affiliate news and email partners was compensated three thousand for the distribution and publication of company news .
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner
"We are encouraged that our first three portfolio companies are generating revenue and expanding operations," said Bryce Knight, CEO of LAST. He added "We are excited to bring new team members into the LAST network to support the growth of these companies and to continue developing our second class of companies under the LAST umbrella."
About Los Angeles Syndicate of Technology - www.last.vc
Los Angeles Syndicate of Technology, Inc. (OTC: LAST.OB) is a publicly traded Business Development Company (BDC) that creates, builds, and invests in web and mobile technology companies. LAST develops digital media, consumer internet, and social networking products in its technology incubator, and has a portfolio of six companies at different stages of development. LAST's mission is to foster technology innovation in Los Angeles by partnering with the most talented entrepreneurs of southern California and providing them with the capital, support and tools to bring their ideas to market and commercialize their products.
About Sanguine Biosciences, Inc. - sanguinebio.com
Sanguine Biosciences, Inc. ("Sanguine") is an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines. Sanguine provides highly viable primary human cells and tissues to both the academic and industrial life science research communities through a new direct-to-patient platform. The current product offering spans customers' needs in the In Vitro Research & Development stage of Drug Development. Sanguine's vision is to develop into the global leader in high quality cells and tissues for life science research and development.
About Virurl, Inc. - virurl.com
Virurl, Inc. ("Virurl") is an online advertising platform that allows advertisers to incentivize people to share links with their friends. By creating a forum where users are rewarded for sharing links, the VIRURL platform empowers content creators and advertisers to tap the organic social networks of the web to drive traffic to their sites. Virurl is a "human-powered" advertising engine, enabling users to earn cash and rewards for what they are already doing everyday - sharing links with their friends.
About Stocktown Productions, Inc. - stocktownproductions.com
Stocktown Productions, Inc. ("Stocktown") is a digital production studio based in Santa Monica, California, specializing in video, animation and 3-D visual effects. In addition to video production, Stocktown provides innovative web and graphic design - bringing an original style and cutting-edge concepts to each project.
Forward-Looking Statements
Statements included in this release related to Los Angeles Syndicate of Technology, Inc. and its portfolio companies constitute or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the inherent uncertainty of investing in early-stage technology companies, the technological and financial difficulties inherent in these activities, and the Company's ability to estimate accurately net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the Company's reports filed with the Securities and Exchange Commission.
Contact Information
Contact:
Los Angeles Syndicate of Technology, Inc.
Bryce Knight
310) 694-0640
www.last.vc
Published at Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure- Investorideas.com and its affiliate news and email partners was compensated three thousand for the distribution and publication of company news .
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Biotech Investor News: (OTCQB: LAST) Portfolio Company, Sanguine BioSciences, Appoints Leader in Genomic and Biomarker Research to Scientific Advisory Board
SANTA MONICA, CA - April 10, 2012 (Investorideas.com Newswire) - Los Angeles Syndicate of Technology, Inc. ( OTCQB: LAST), a publicly-traded venture fund and technology incubator, is pleased to announce that its portfolio company, Sanguine BioSciences, Inc. ("Sanguine"), has appointed Dr. Timothy J. Triche, MD, PhD to Sanguine's Scientific Advisory Board. Sanguine Biosciences, Inc., an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines, was developed in LAST's technology incubator.
"We are pleased to announce Professor Triche's appointment to our Scientific Advisory Board," said Brian Neman, Sanguine's Chairman and Chief Executive Officer. "Dr. Triche has been a leader in genomic and biomarker research for decades, and provides the company with valuable strategic insight as the company is poised to begin digitizing biological and clinical data within its bio-repository."
Professor Timothy J. Triche, of the Center for Personalized Medicine (CPM) at Children's Hospital Los Angeles / University of Southern California, has more than 40 years of experience in Pathology and Laboratory Medicine. As the Director of the CPM, Dr. Triche coordinates, supports, and expands the hospital's basic and translational research objectives in genomics, proteomics, bioinformatics, molecular genetics, molecular microbiology and cytogenetics. Dr. Triche formerly held the position of director of Specialized Diagnostics, Pathology, at the National Institutes of Health and section chief in the Laboratory of Pathology at the National Cancer Institute of the National Institutes of Health, from 1975 to 1988.
Dr. Triche has authored over 188 peer-reviewed publications, 176 abstracts and 39 book chapters and his research has been funded by major organizations such as the National Cancer Institute, the Whittier Foundation, the Department of Energy, and the Department of Defense.
About Los Angeles Syndicate of Technology - www.last.vc
Los Angeles Syndicate of Technology, Inc. (OTC: LAST) is a publicly traded Business Development Company (BDC) operating as a venture fund and technology incubator that creates, builds, and invests in web and mobile technology companies. LAST develops digital media, social networking, and life sciences products in its technology incubator, and has a portfolio of six companies at different stages of development. LAST's mission is to foster technology innovation in Los Angeles by partnering with the most talented entrepreneurs of southern California and providing them with the capital, supp ort and tools to bring their ideas to market and commercialize their products.
About Sanguine Biosciences, Inc. - sanguinebio.com
Sanguine Biosciences, Inc. ("Sanguine") is an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines.Sanguine provides highly viable primary human cells and tissues to both the academic and industrial life science research communities through a new direct-to-patient platform. The current product offering spans customers' needs in the In Vitro Research & Development stage of Drug Development. Sanguine's vision is to develop into the global leader in high quality cells and tissues for life science research and development.
Forward-Looking Statements
Statements included in this release related to Los Angeles Syndicate of Technology, Inc. and its portfolio companies constitute or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the inherent uncertainty of investing in early-stage technology companies, the technological and financial difficulties inherent in these activities, and the Company's ability to estimate accurately net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the Company's reports filed with the Securities and Exchange Commission.
Contact Information
Contact:
Los Angeles Syndicate of Technology, Inc.
Bryce Knight
(310) 694-0640
www.last.vc
Published at Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure- Investorideas.com and its affiliate news and email partners was compensated three thousand for the distribution and publication of company news .
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
"We are pleased to announce Professor Triche's appointment to our Scientific Advisory Board," said Brian Neman, Sanguine's Chairman and Chief Executive Officer. "Dr. Triche has been a leader in genomic and biomarker research for decades, and provides the company with valuable strategic insight as the company is poised to begin digitizing biological and clinical data within its bio-repository."
Professor Timothy J. Triche, of the Center for Personalized Medicine (CPM) at Children's Hospital Los Angeles / University of Southern California, has more than 40 years of experience in Pathology and Laboratory Medicine. As the Director of the CPM, Dr. Triche coordinates, supports, and expands the hospital's basic and translational research objectives in genomics, proteomics, bioinformatics, molecular genetics, molecular microbiology and cytogenetics. Dr. Triche formerly held the position of director of Specialized Diagnostics, Pathology, at the National Institutes of Health and section chief in the Laboratory of Pathology at the National Cancer Institute of the National Institutes of Health, from 1975 to 1988.
Dr. Triche has authored over 188 peer-reviewed publications, 176 abstracts and 39 book chapters and his research has been funded by major organizations such as the National Cancer Institute, the Whittier Foundation, the Department of Energy, and the Department of Defense.
About Los Angeles Syndicate of Technology - www.last.vc
Los Angeles Syndicate of Technology, Inc. (OTC: LAST) is a publicly traded Business Development Company (BDC) operating as a venture fund and technology incubator that creates, builds, and invests in web and mobile technology companies. LAST develops digital media, social networking, and life sciences products in its technology incubator, and has a portfolio of six companies at different stages of development. LAST's mission is to foster technology innovation in Los Angeles by partnering with the most talented entrepreneurs of southern California and providing them with the capital, supp ort and tools to bring their ideas to market and commercialize their products.
About Sanguine Biosciences, Inc. - sanguinebio.com
Sanguine Biosciences, Inc. ("Sanguine") is an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines.Sanguine provides highly viable primary human cells and tissues to both the academic and industrial life science research communities through a new direct-to-patient platform. The current product offering spans customers' needs in the In Vitro Research & Development stage of Drug Development. Sanguine's vision is to develop into the global leader in high quality cells and tissues for life science research and development.
Forward-Looking Statements
Statements included in this release related to Los Angeles Syndicate of Technology, Inc. and its portfolio companies constitute or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the inherent uncertainty of investing in early-stage technology companies, the technological and financial difficulties inherent in these activities, and the Company's ability to estimate accurately net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the Company's reports filed with the Securities and Exchange Commission.
Contact Information
Contact:
Los Angeles Syndicate of Technology, Inc.
Bryce Knight
(310) 694-0640
www.last.vc
Published at Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure- Investorideas.com and its affiliate news and email partners was compensated three thousand for the distribution and publication of company news .
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Wednesday, April 4, 2012
Biotech Alert: PositiveID (OTCBB: PSID); Big Ambitions for Biodefense and Diabetes Markets for 2012
New York, NY - April 4, 2012 - (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents its second exclusive Q&A interview with Medical technology stock, PositiveID Corporation (OTCBB: PSID). Mr. William J. Caragol, Chairman and Chief Executive Officer, illuminates on the first quarter operational highlights that have positioned the Company in the diabetes and biodefense markets for 2012.
Q: Investorideas.com
Mr. Caragol, the biggest opportunity currently in front of your company for 2012 and beyond is theDepartment of Homeland Security's $3.1 billion BioWatch Gen-3 contract for your M-BAND airborne bio-threat detection system. Skeptical investors would ask how a small company like yours realistically plans to gain a piece of this high profile deal. Can you elaborate on what makes your technology a game changer and what your business strategy has been for entering in the defense playing field?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
By way of background, PositiveID's M-BAND, developed under contract for the Department of Homeland Security over the past eight years by our Microfluidic Systems (MFS) subsidiary, is an early warning system designed to detect the intentional release of aerosolized biological agents. It runs autonomously for up to 30 days, which is longer than competing systems, and continuously analyzes air samples, typically in high-traffic areas, for the detection of bacteria, viruses, and toxins with results in as little as three hours. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments in aggregate.
We believe we are well positioned for Gen-3 of Biowatch, as M-BAND is one of only two technologies that are compatible with DHS' procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years. This opportunity represents a very significant opportunity for PositiveID as the owner of the M-BAND technology. In order to effectively compete for this draft RFP, expected later this year, we plan to partner with much larger organizations including manufacturers and systems integrators that are well versed in government procurements.
Q: Investorideas.com
What has been put in place for the diabetes management products, Easy Check(TM) and GlucoChip(TM) for the first quarter and how will these developments change the complexion of the Company for 2012?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
As you know, diabetes continues to grow to epidemic proportions both in the U.S. and across the globe. An estimated 26 million children and adults in the United States and more than 346 million people worldwide are believed to have the disease. The pain and inconvenience associated with drawing blood each time a blood sugar reading is needed is one of the causes of poor patient compliance with diabetes management. Therefore, we believe providing a non-invasive measurement of blood glucose or an in vivo glucose-sensing system for people with diabetes could vastly improve disease management and health outcomes, and thereby decrease costs to the healthcare system.
To that end, in the first quarter we made significant progress with both Easy Check and GlucoChip. Easy Check is a non-invasive breath glucose detection device that measures the level of acetone in a diabetic patient's exhaled breath and correlates that acetone level to a measure of blood glucose. In February, we commenced our first clinical trial of Easy Check, which is being held at Schneider Children's Medical Center in Israel, a preeminent research hospital, and is initially focused on people with type 1 diabetes. If we are successful with our continued development of Easy Check and bring this product to market, Easy Check could eliminate the need for a person with diabetes to prick his or her finger in order to get a blood glucose measurement.
GlucoChip is a continuous glucose-sensing microchip currently under development with our partner RECEPTORS LLC. In March, we announced we completed the first-in-class development of the glucose-sensing system – a fully synthetic, stable, sensitive, selective sensing system that is responsive to glucose in human plasma. This is a key milestone in our development of GlucoChip and is considered to be a critical step in the development of an artificial pancreas for people with type 1 diabetes.
Q: Investorideas.com
The Company was granted the U.S. Patent for first-of-its-kind Dragonfly detection system for molecular biological diagnostics. What is the significance of this to the Company in the short and long term?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Dragonfly is basically a miniaturized version of our M-BAND system, or a “lab in a box” as we call it. Dragonfly delivers molecular diagnostic results, which are very specific and highly accurate, from a patient sample in less than 30 minutes at the point-of-care. The benefit of Dragonfly is that tests do not have to be sent out and performed at other labs with expensive equipment and healthcare professionals and patients do not have to wait days or longer for test results and proper treatment. Put simply, Dragonfly enables accurate diagnostics leading to the potential treatment scenarios at the point of care that are not possible with existing systems.
PositiveID believes its Dragonfly technology, which has been proven for illnesses such as influenza, MRSA, human papilloma virus (HPV) and others, will help the Company break into the clinical diagnostic market and create important partnership opportunities.
Q: Investorideas.com
In closing, referencing back to the first question of how a small company like PositiveID has positioned itself in two very significant market opportunities in biodefense and diabetes, the biggest question is always how does a small company not get eaten by the giants in the process
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
PositiveID is a small, but innovative, technology development company. We look to acquire interesting and promising intellectual property, and develop those exciting technologies for unmet market needs. Once the development of any or all of our technologies is complete and products are ready for commercialization, we look to partner with the appropriate organizations to maximize the opportunities at hand.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Learn more about PSID at Investorideas.com
http://www.investorideas.com/CO/PSID/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation ( OTCBB:PSID ) featured biotech company on Investorideas.com for 3 months effective January 30, 2012. Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact Investorideas.com 800 665 0411
Or
For info on the Company contact
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Q: Investorideas.com
Mr. Caragol, the biggest opportunity currently in front of your company for 2012 and beyond is theDepartment of Homeland Security's $3.1 billion BioWatch Gen-3 contract for your M-BAND airborne bio-threat detection system. Skeptical investors would ask how a small company like yours realistically plans to gain a piece of this high profile deal. Can you elaborate on what makes your technology a game changer and what your business strategy has been for entering in the defense playing field?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
By way of background, PositiveID's M-BAND, developed under contract for the Department of Homeland Security over the past eight years by our Microfluidic Systems (MFS) subsidiary, is an early warning system designed to detect the intentional release of aerosolized biological agents. It runs autonomously for up to 30 days, which is longer than competing systems, and continuously analyzes air samples, typically in high-traffic areas, for the detection of bacteria, viruses, and toxins with results in as little as three hours. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments in aggregate.
We believe we are well positioned for Gen-3 of Biowatch, as M-BAND is one of only two technologies that are compatible with DHS' procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years. This opportunity represents a very significant opportunity for PositiveID as the owner of the M-BAND technology. In order to effectively compete for this draft RFP, expected later this year, we plan to partner with much larger organizations including manufacturers and systems integrators that are well versed in government procurements.
Q: Investorideas.com
What has been put in place for the diabetes management products, Easy Check(TM) and GlucoChip(TM) for the first quarter and how will these developments change the complexion of the Company for 2012?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
As you know, diabetes continues to grow to epidemic proportions both in the U.S. and across the globe. An estimated 26 million children and adults in the United States and more than 346 million people worldwide are believed to have the disease. The pain and inconvenience associated with drawing blood each time a blood sugar reading is needed is one of the causes of poor patient compliance with diabetes management. Therefore, we believe providing a non-invasive measurement of blood glucose or an in vivo glucose-sensing system for people with diabetes could vastly improve disease management and health outcomes, and thereby decrease costs to the healthcare system.
To that end, in the first quarter we made significant progress with both Easy Check and GlucoChip. Easy Check is a non-invasive breath glucose detection device that measures the level of acetone in a diabetic patient's exhaled breath and correlates that acetone level to a measure of blood glucose. In February, we commenced our first clinical trial of Easy Check, which is being held at Schneider Children's Medical Center in Israel, a preeminent research hospital, and is initially focused on people with type 1 diabetes. If we are successful with our continued development of Easy Check and bring this product to market, Easy Check could eliminate the need for a person with diabetes to prick his or her finger in order to get a blood glucose measurement.
GlucoChip is a continuous glucose-sensing microchip currently under development with our partner RECEPTORS LLC. In March, we announced we completed the first-in-class development of the glucose-sensing system – a fully synthetic, stable, sensitive, selective sensing system that is responsive to glucose in human plasma. This is a key milestone in our development of GlucoChip and is considered to be a critical step in the development of an artificial pancreas for people with type 1 diabetes.
Q: Investorideas.com
The Company was granted the U.S. Patent for first-of-its-kind Dragonfly detection system for molecular biological diagnostics. What is the significance of this to the Company in the short and long term?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Dragonfly is basically a miniaturized version of our M-BAND system, or a “lab in a box” as we call it. Dragonfly delivers molecular diagnostic results, which are very specific and highly accurate, from a patient sample in less than 30 minutes at the point-of-care. The benefit of Dragonfly is that tests do not have to be sent out and performed at other labs with expensive equipment and healthcare professionals and patients do not have to wait days or longer for test results and proper treatment. Put simply, Dragonfly enables accurate diagnostics leading to the potential treatment scenarios at the point of care that are not possible with existing systems.
PositiveID believes its Dragonfly technology, which has been proven for illnesses such as influenza, MRSA, human papilloma virus (HPV) and others, will help the Company break into the clinical diagnostic market and create important partnership opportunities.
Q: Investorideas.com
In closing, referencing back to the first question of how a small company like PositiveID has positioned itself in two very significant market opportunities in biodefense and diabetes, the biggest question is always how does a small company not get eaten by the giants in the process
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
PositiveID is a small, but innovative, technology development company. We look to acquire interesting and promising intellectual property, and develop those exciting technologies for unmet market needs. Once the development of any or all of our technologies is complete and products are ready for commercialization, we look to partner with the appropriate organizations to maximize the opportunities at hand.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Learn more about PSID at Investorideas.com
http://www.investorideas.com/CO/PSID/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation ( OTCBB:PSID ) featured biotech company on Investorideas.com for 3 months effective January 30, 2012. Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact Investorideas.com 800 665 0411
Or
For info on the Company contact
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Monday, April 2, 2012
Medical Technology Stock Alert; PositiveID Corporation (OTCBB:PSID) Announces First Quarter 2012 Accomplishments: Positions Itself for $3 Billion BioWatch Contract and Advances the Development of Its Diabetes Management Products
DELRAY BEACH, Fla. - April 2, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense industry, today announced its accomplishments for the first quarter of 2012, including its positioning for the $3.1 billion BioWatch contract and the continued progress with the Company's development and clinical study of its innovative diabetes management products.
PositiveID's First Quarter 2012 Operational Highlights
Positioned its M-BAND airborne bio-threat detection system to take part in the Department of Homeland Security's $3.1 billion BioWatch Gen-3 opportunity, which is expected to be released in the third quarter of 2012
Partnered with the Diabetes Research Institute at the University of Miami and Schneider Children's Medical Center of Israel to support the development of the Company's diabetes management products, including Easy Check(TM) and GlucoChip(TM)
Commenced clinical study of PositiveID's Easy Check, a non-invasive breath glucose detection device, at Schneider Children's Medical Center of Israel under the leadership of world-renowned endocrinologist Prof. Moshe Phillip; the study is expected to be completed by year-end 2012
Finalized its first-in-class development of a fully synthetic glucose sensing system to be used in its GlucoChip and measure glucose levels within the body, which is considered to be a critical step in the development of an artificial pancreas
Awarded U.S. Patent for first-of-its-kind Dragonfly detection system for molecular biological diagnostics
"We continued to make great strides in all areas of our business in the first quarter of 2012, and are executing on our plan to bring these important technologies to market," stated William J. Caragol, Chairman and CEO of PositiveID. "We are seeing early positive results from our Easy Check testing, and remain optimistic that the significant benefits of our M-BAND system set us apart from the competition, thereby solidifying our position with large partners for the $3.1 billion BioWatch opportunity. Additionally, we are preparing for the initial roll-out of our FDA-cleared iglucose in the second quarter of this year through home-healthcare providers and healthcare insurers."
M-BAND is the only system of its kind that was demonstrated in the field under the DHS Science and Technology ("S&T") BAND Program. PositiveID's patented M-BAND biodetector was developed under a competitive award from DHS S&T, and M-BAND was the only successful system to emerge from the BAND program. BioWatch program is the nation's first early warning network of sensors to detect biological attacks. Because of the rapid decision cycle and the need for a deployment of medical countermeasures, the ability to quickly identify a biological agent will potentially save lives. Generation 3 of BioWatch is a planned, $3.1 billion procurement. At present, the Company believes there are only two technologies, one of which is its own M-BAND system, which can meet the requirements of Generation 3 BioWatch.
Designed in a miniaturized format for use at the point-of-care or in the field, PositiveID's Dragonfly(TM) Rapid MDx Cartridge-based diagnostic system provides the ability to deliver molecular diagnostic results from a sample in less than 30 minutes. Dragonfly has been proven effective for a broad range of biological detection including radiation-induced cell damage within the human body, strains of influenza and other common pathogens and diseases such as E. coli, methicillin-resistant staphylococcus aureus (MRSA) and human papilloma virus (HPV). The system offers the precision of molecular diagnostics in an easy-to-use cartridge format that minimizes the possibility of human error. Typical current molecular diagnostic testing can take hours or even days, requires highly trained personnel and includes multiple handling steps. Dragonfly enables accurate diagnostics leading to the potential treatment scenarios at the point of care that are not possible with existing systems, thereby positioning PositiveID to enter the clinical diagnostics market.
PositiveID's Easy Check, currently under development in Israel, is a non-invasive breath glucose detection device that measures the level of acetone in a patient's exhaled breath and correlates that acetone level to a measure of blood glucose. The Easy Check technology is based on a patent-pending reagent cell that mixes a patient's exhaled air with a proprietary chemical compound, triggering a chemical reaction. The reaction is measured and software in the Easy Check device then interprets the measurement and correlates the patient's acetone level to the level of glucose in the body. The goal of Easy Check is to eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading. With the American Diabetes Association estimating that over 25.8 million children and adults in the United States, or 8.3 percent of the population have diabetes, the overall market for a device such as Easy Check remains a significant opportunity for the Company.
Positioned for the same sizable market, PositiveID has completed its first-in-class development of a fully synthetic glucose sensing system that is the mission-critical component of its GlucoChip, a glucose-sensing microchip to measure glucose levels within the body for people with diabetes. PositiveID and its partner RECEPTORS LLC believe they are the first to develop a fully synthetic, stable, sensitive, selective sensing system that is responsive to glucose in human plasma, which is considered to be a critical step in the development of an artificial pancreas. GlucoChip is based on PositiveID's Patent No. 7,125,382 for an "Embedded Bio-Sensor System."
PositiveID's FDA-cleared iglucose(TM) system is a wireless communication device that eliminates the burden of keeping manual logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose uses mobile technology to seamlessly communicate blood glucose readings from an individual's data-capable glucometer to the iglucose diabetes management portal, where, with the user's consent, glucose readings can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax. iglucose does not require the use of a cell phone or a wireless plan. The Company expects the initial roll-out of iglucose to commence in the second quarter of 2012.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
PositiveID's First Quarter 2012 Operational Highlights
Positioned its M-BAND airborne bio-threat detection system to take part in the Department of Homeland Security's $3.1 billion BioWatch Gen-3 opportunity, which is expected to be released in the third quarter of 2012
Partnered with the Diabetes Research Institute at the University of Miami and Schneider Children's Medical Center of Israel to support the development of the Company's diabetes management products, including Easy Check(TM) and GlucoChip(TM)
Commenced clinical study of PositiveID's Easy Check, a non-invasive breath glucose detection device, at Schneider Children's Medical Center of Israel under the leadership of world-renowned endocrinologist Prof. Moshe Phillip; the study is expected to be completed by year-end 2012
Finalized its first-in-class development of a fully synthetic glucose sensing system to be used in its GlucoChip and measure glucose levels within the body, which is considered to be a critical step in the development of an artificial pancreas
Awarded U.S. Patent for first-of-its-kind Dragonfly detection system for molecular biological diagnostics
"We continued to make great strides in all areas of our business in the first quarter of 2012, and are executing on our plan to bring these important technologies to market," stated William J. Caragol, Chairman and CEO of PositiveID. "We are seeing early positive results from our Easy Check testing, and remain optimistic that the significant benefits of our M-BAND system set us apart from the competition, thereby solidifying our position with large partners for the $3.1 billion BioWatch opportunity. Additionally, we are preparing for the initial roll-out of our FDA-cleared iglucose in the second quarter of this year through home-healthcare providers and healthcare insurers."
M-BAND is the only system of its kind that was demonstrated in the field under the DHS Science and Technology ("S&T") BAND Program. PositiveID's patented M-BAND biodetector was developed under a competitive award from DHS S&T, and M-BAND was the only successful system to emerge from the BAND program. BioWatch program is the nation's first early warning network of sensors to detect biological attacks. Because of the rapid decision cycle and the need for a deployment of medical countermeasures, the ability to quickly identify a biological agent will potentially save lives. Generation 3 of BioWatch is a planned, $3.1 billion procurement. At present, the Company believes there are only two technologies, one of which is its own M-BAND system, which can meet the requirements of Generation 3 BioWatch.
Designed in a miniaturized format for use at the point-of-care or in the field, PositiveID's Dragonfly(TM) Rapid MDx Cartridge-based diagnostic system provides the ability to deliver molecular diagnostic results from a sample in less than 30 minutes. Dragonfly has been proven effective for a broad range of biological detection including radiation-induced cell damage within the human body, strains of influenza and other common pathogens and diseases such as E. coli, methicillin-resistant staphylococcus aureus (MRSA) and human papilloma virus (HPV). The system offers the precision of molecular diagnostics in an easy-to-use cartridge format that minimizes the possibility of human error. Typical current molecular diagnostic testing can take hours or even days, requires highly trained personnel and includes multiple handling steps. Dragonfly enables accurate diagnostics leading to the potential treatment scenarios at the point of care that are not possible with existing systems, thereby positioning PositiveID to enter the clinical diagnostics market.
PositiveID's Easy Check, currently under development in Israel, is a non-invasive breath glucose detection device that measures the level of acetone in a patient's exhaled breath and correlates that acetone level to a measure of blood glucose. The Easy Check technology is based on a patent-pending reagent cell that mixes a patient's exhaled air with a proprietary chemical compound, triggering a chemical reaction. The reaction is measured and software in the Easy Check device then interprets the measurement and correlates the patient's acetone level to the level of glucose in the body. The goal of Easy Check is to eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading. With the American Diabetes Association estimating that over 25.8 million children and adults in the United States, or 8.3 percent of the population have diabetes, the overall market for a device such as Easy Check remains a significant opportunity for the Company.
Positioned for the same sizable market, PositiveID has completed its first-in-class development of a fully synthetic glucose sensing system that is the mission-critical component of its GlucoChip, a glucose-sensing microchip to measure glucose levels within the body for people with diabetes. PositiveID and its partner RECEPTORS LLC believe they are the first to develop a fully synthetic, stable, sensitive, selective sensing system that is responsive to glucose in human plasma, which is considered to be a critical step in the development of an artificial pancreas. GlucoChip is based on PositiveID's Patent No. 7,125,382 for an "Embedded Bio-Sensor System."
PositiveID's FDA-cleared iglucose(TM) system is a wireless communication device that eliminates the burden of keeping manual logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose uses mobile technology to seamlessly communicate blood glucose readings from an individual's data-capable glucometer to the iglucose diabetes management portal, where, with the user's consent, glucose readings can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax. iglucose does not require the use of a cell phone or a wireless plan. The Company expects the initial roll-out of iglucose to commence in the second quarter of 2012.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Subscribe to:
Posts (Atom)